Clinical trials: Cytomegalovirus Prophylaxis
Cytomegalovirus Infection Reactivation
Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT
To explore the effect of letermovir prophylaxis on cytomegalovirus-specific immune reconstitution post unrelated cord blood transplantation
- Trial name
- NCT06441669
- Testing
- Letermovir
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Anhui Provincial Hospital
Cytomegalovirus Disease
TT-CMV Observational Birth Cohort Study
The spread of viruses through transfusions is the cause of serious illness and death in recipients whose immune systems are unable to fight infection.
- Trial name
- TT-CMV (NCT00907686)
- Where
- 3 sites in United States
- Volunteers
- 600 people
- Sponsor
- Emory University
Lung Transplant; Complications
CMV Immunity Monitoring in Lung Transplant Recipients
The purpose of this study is to determine the safety and feasibility of using a laboratory test to guide duration of antiviral prophylaxis with valganciclovir (medication used to prevent viral infections) after lung transplant.
- Trial name
- NCT05708755
- Testing
- Cytomegalovirus T Cell Immunity Panel (CMV-TCIP), Donor-Derived Cell-Free DNA (dd-cfDNA) Assay, Valganciclovir
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- NYU Langone Health
CMV
Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy
Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality for recipients of allogeneic hematopoietic stem cell transplantation(HSCT).
- Trial name
- INMUNOCELL (NCT04056533)
- Testing
- CMV CTLs
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation
Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT
To evaluate the efficacy and safety of primary prophylaxis of CMV reactivation, clinically significant CMV infection with oral letermovir in Chinese R+ haplo-HSCT patients, as well as treatment-related mortality and all-cause…
- Trial name
- NCT05914675
- Testing
- Letermovir
- Volunteers
- 21 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Critical Illness
Cytomegalovirus Control in Critical Care
The purpose of this study is to determine whether reactivation of latent cytomegalovirus infection in critically ill patients looked after in the intensive care unit can be successfully and safely prevented using antiviral…
- Trial name
- CCCC (NCT01503918)
- Testing
- Valaciclovir/Aciclovir, Valganciclovir/Ganciclovir
- Where
- United Kingdom
- Volunteers
- 124 people
- Sponsor
- University Hospital Birmingham NHS Foundation Trust
Cytomegalovirus Disease
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease
To compare the efficacy of oral brincidofovir (BCV) to valganciclovir (vGCV) for the prevention of cytomegalovirus (CMV) disease in kidney transplant allograft recipients who are CMV seronegative pretransplant and received a…
- Trial name
- SUSTAIN (NCT02439970)
- Testing
- Brincidofovir, Valganciclovir
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Jazz Pharmaceuticals
Bone Marrow Transplantation, Cytomegalovirus
Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT)
The rationale for this protocol is based on the need to assess if the current post stem cell transplantation CMV prophylaxis strategies (e.g.
- Trial name
- NCT00330018
- Testing
- Valganciclovir, Acyclovir
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Hadassah Medical Organization
Transplantation Infection, Cytomegalovirus Infections
Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients.
To assess the efficacy of reduced duration prophylaxis followed by immuno-guided prophylaxis to prevent cytomegalovirus disease.
- Trial name
- CYTOCOR (NCT03699254)
- Testing
- Valganciclovir, Ganciclovir
- Where
- 7 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Immunoglobulin Prophylaxis, Cytomegalovirus Infections
Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Human cytomegalovirus (CMV) is a globally prevalent, human-specific herpesvirus characterised by a lifelong latency after primary infection, an often asymptomatic reactivation and affecting up to 100% of adults based on region…
- Conditions
- Immunoglobulin Prophylaxis, Cytomegalovirus Infections, Allogeneic Hematopoietic Stem Cell Transplantation, Transplant-Related Disorder
- Trial name
- NCT07013370
- Testing
- Anti-CMV immunoglobulins [Megalotect (R)]
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Antonello Di Paolo, M.D., Ph.D.
Adenovirus Infection, BK Virus Infection
Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
This is a Phase 2 study to evaluate posoleucel (ALVR105, formerly Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr…
- Conditions
- Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections
- Trial name
- Prevent (NCT04693637)
- Testing
- Posoleucel (ALVR105)
- Where
- 16 sites in United States
- Volunteers
- 26 people
- Sponsor
- AlloVir
Cell Therapy
Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell
The goal of this clinical research study is to learn if a drug called Letermovir can help to prevent CMV reactivation.
- Trial name
- NCT06575374
- Testing
- Letermovir
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center